Nightfood Holdings Inc. (OTCQB: NGTF), operating through its TechForce Robotics subsidiary, announced the advancement of Phase 2 objectives under its joint development collaboration with Oncotelic Therapeutics (OTCQB: OTLC). The milestone is highlighted by the deployment of PUR-E, an autonomous clean room support robot, within SAPU Bio’s OEB-5 sterile injectable cGMP facility. This deployment expands the initiative beyond Phase 1 materials logistics operations and into sterile manufacturing and clean room environments, where TechForce and Oncotelic are evaluating robotics, automation and AI-driven technologies to support regulated pharmaceutical workflows.
PUR-E joins TechForce’s LIM-E autonomous GMP support robot at the SAPU Bio facility. The systems are being used to assess opportunities in sterile manufacturing operations, electronic batch record processes and other cGMP activities. According to the companies, the initiative is part of a broader effort to develop robotics and automation solutions for pharmaceutical manufacturing, biotechnology and life sciences environments, with PUR-E operating as part of TechForce’s Robotics-as-a-Service Provider (RaaSP) platform.
The deployment of PUR-E into a sterile, high-containment environment represents a significant step forward in automating pharmaceutical manufacturing. OEB-5 facilities handle highly potent compounds, and the introduction of autonomous robots can reduce human exposure to hazardous materials, improve consistency in clean room operations, and enhance overall safety and efficiency. For the pharmaceutical industry, this could lead to faster production cycles, lower contamination risks, and reduced operational costs.
Nightfood Holdings, doing business as TechForce Robotics, is an AI-enhanced robotics and automation company focused on developing and deploying intelligent automation solutions across multiple industries. The company operates through a vertically integrated business model that combines proprietary robotics technology, AI-enhanced software, real-world operating environments, strategic manufacturing partnerships, and scalable deployment infrastructure. By integrating advanced robotics, machine vision, intelligent automation, and data-driven operational insights, TechForce Robotics seeks to address growing labor challenges and productivity demands.
Nightfood delivers its solutions through a Robotics-as-a-Service (RaaS) model, providing customers with flexible, scalable automation solutions while generating recurring revenue opportunities. As the company expands into pharmaceutical automation, laboratory automation, industrial automation, and other high-precision applications, it continues to leverage strategic partnerships and advanced engineering capabilities to accelerate innovation and commercialization.
For investors and industry observers, this advancement signals the growing intersection of robotics and pharmaceutical manufacturing. The successful deployment of autonomous systems in sterile environments could pave the way for broader adoption of automation in regulated industries, potentially transforming how drugs are manufactured and quality-controlled. The implications extend to cost savings, faster time-to-market for critical medications, and enhanced worker safety.
More information about Nightfood Holdings is available in the company’s newsroom at http://ibn.fm/NGTF. The full press release can be viewed at https://ibn.fm/mXU1p.
